The US FDA continues to give overly optimistic predictions of median ANDA times to approval, a popular performance measure for the generic drugs program.
ANDA Approval Times Get Optimistic Estimate In Budget Request
US FDA has historically overestimated generic review performance in budget requests, but recently underestimated the number of ANDAs it expects to approve.
More from US FDA
• By
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
• By
Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.